Clopidogrel intravenous - Ligand Pharmaceuticals
Alternative Names: Captisol-Enabled® clopidogrel; Clopidogrel intravenous - CyDex; MDCO-157; PM 103; sulfobutylether β-cyclodextrin-enabled clopidogrelLatest Information Update: 23 Dec 2021
At a glance
- Originator CyDex Pharmaceuticals; Prism Pharmaceuticals
- Developer Ligand Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Coronary thrombosis
Most Recent Events
- 30 Jun 2013 The Medicines Company and Ligand Pharmaceuticals terminate their licensing agreement for intravenous clopidogrel
- 31 Jan 2013 The Medicines Company completes a phase I trial in healthy volunteers in France (NCT01860105)
- 30 Sep 2012 The Medicines Company initiates enrolment in a phase I bioequivalence trial for Coronary thrombosis prevention